Key result
In vivo treatment with levamisole restored low lymphocyte response to mitogens in patients with rheumatoid arthritis, suggesting intrinsic defects cause the decreased cellular response.
Why the study?
Does levamisole improve lymphocyte response to mitogens in patients with rheumatoid arthritis?
Observational
Does levamisole improve lymphocyte response to mitogens in patients with rheumatoid arthritis?
Levamisole can restore the intrinsically defective lymphocyte response to mitogens in patients with rheumatoid arthritis.
Answers are grounded in this paper and cite their sources.
May support levamisole to restore mitogen responses in RA; leaves open clinical benefit and requires controlled trials.
The mechanism of poor lymphocyte transformation to mitogens was studied in selected patients with rheumatoid arthritis and systemic lupus erythematosus. Low lymphocyte response to PHA and Con-A in media containing autologous and homologous sera was usually associated with poor response to the calcium ionophore A23187, which induces blastogenesis by a different mechanism. The low lymphocyte response to mitogens in patients with rheumatoid arthritis could be restored by in vivo treatment with the anthelmintic drug, levamisole. The present findings suggest that intrinsic defects are responsible for the decreased cellular response in patients with rheumatoid arthritis and systemic lupus erythematosus.
No takes yet. Share an insight, caveat, or question.
Scheinberg et al. (1978) conducted an observational in Rheumatoid arthritis and systemic lupus erythematosus. Levamisole was evaluated on Lymphocyte response to mitogens. In vivo treatment with levamisole restored low lymphocyte response to mitogens in patients with rheumatoid arthritis, suggesting intrinsic defects cause the decreased cellular response.
Synapse has enriched 10 related papers. Consider them for comparative context: